Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$2.63
-$0.01(-0.44%)
At close: 4:00 PM EDT
$2.63
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.66 - $3.72
Previous Close$2.28
Volume807.02K
Average Volume (3M)775.44K
Market Cap
$128.21M
Enterprise Value$101.60M
Total Cash (Recent Filing)$182.76M
Total Debt (Recent Filing)$73.54M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding71,624,794
10 Day Avg. Volume1,158,251
30 Day Avg. Volume775,439
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.42
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$11.75Price Target Upside346.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageModerate leverage gives Nkarta more financial flexibility than a heavily indebted early-stage biotech. Debt is present but not overwhelming relative to equity, which may help preserve strategic options while the company advances its pipeline toward potential revenue.
Improving Cash-Flow TrendAlthough cash flow remains materially negative, the reduced severity of free-cash-flow losses and positive recent growth indicate some improvement in cash usage. If sustained, this trend could extend the company’s operating runway and reduce the pace of future financing needs.
Stable Loss ProfileThe absence of meaningful further deterioration versus 2023 suggests Nkarta’s losses have not accelerated indefinitely. This stability does not establish profitability, but it provides a more predictable base for managing research investment and evaluating progress toward eventual commercialization.
Bears Say
No Revenue BaseNkarta has no established revenue stream to fund operations, validate commercial demand, or offset research spending. As a pre-revenue biotech, its financial outlook remains dependent on advancing development programs and ultimately achieving successful commercialization.
Persistent Operating LossesLarge and persistent operating losses show that Nkarta’s current business model consumes substantial resources without producing earnings. Continued losses can erode equity, constrain investment capacity, and increase the importance of successful clinical and commercial execution.
Material Cash BurnSustained negative operating and free cash flow means Nkarta cannot currently finance its activities from internally generated funds. The stated reliance on financing to fund operations creates ongoing funding requirements and leaves the company exposed to dilution or other financing constraints.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.66 and its highest was $3.72 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $128.21M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Nov 11, 2026 which is in 17 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Aug 10, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.18.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.4.
How many shares outstanding does Nkarta have?
Nkarta has 71,624,794 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -5.285%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (346.77% Upside)
$11.75 (346.77% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 587.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.79%
12-Months-Change
Fundamentals
Return on Equity
-39.64%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nkarta
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.75
▲(346.77% Upside)
Technical Analysis
Ownership Overview
20.62% Insiders
7.76% Mutual Funds
3.20% Other Institutional Investors
61.17% Public Companies and
Individual Investors